635-84-7

Basic information

• Product Name: 4-Phenylphenacyl chloride
• Synonyms: 4-PHENYLPHENACYL CHLORIDE;2-CHLORO-4'-PHENYLACETOPHENONE;2-Chloro-4'-Phenylacetophenone(alpha-);biphenyl-4-yl chloromethyl ketone;p-Phenylphenacyl chloride;4-PHENYL-2''-CHLOROACETOPHENONE;1-Cyano-1-methylpropylamine;3-Amino-3-methylbutanenitrile
• CAS NO: 635-84-7
• Molecular Formula: C₁₄H₁₁ClO
• Molecular Weight: 230.69
• Mol File: 635-84-7.mol
• Article Data: 13

Chemical Properties

• Melting Point: 126°C
• Boiling Point: 366.1 °C at 760 mmHg
• Flash Point: 197.9 °C
• Appearance: Yellow liquid
• Density: 1.167 g/cm³
• Vapor Pressure: 1.49E-05mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: 4-Phenylphenacyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Phenylphenacyl chloride(635-84-7)
• EPA Substance Registry System: 4-Phenylphenacyl chloride(635-84-7)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 635-84-7(Hazardous Substances Data)

Usage

General Description

4-Phenylphenacyl chloride is a chemical compound that is typically used in the field of organic synthesis. This substance, with the molecular formula C14H11ClO, exists as a white solid at room temperature. It can be an irritant to the eyes, skin, and respiratory system. It needs to be properly handled and disposed using approved safety methods. The compound's structure consists of a central carbonyl group (C=O) bonded to a benzene ring and a chloride atom, with an additional phenyl group attached to the benzene ring.

InChI:InChI=1/C14H11ClO/c15-10-14(16)13-8-6-12(7-9-13)11-4-2-1-3-5-11/h1-9H,10H2

Upstream product

• 108-90-7 chlorobenzene 
• 92-52-4 biphenyl 
• 79-04-9 chloroacetyl chloride 
• 108-86-1 bromobenzene 
• 541-88-8 Chloroacetic anhydride 

Downstream Products

• 143888-92-0 2-[2-(2-Biphenyl-4-yl-oxiranyl)-benzyloxy]-tetrahydro-pyran 
• 112934-17-5 N-(2-Biphenyl-4-yl-2-oxo-ethyl)-N-((S)-1-hydroxymethyl-propyl)-4-methyl-benzenesulfonamide 
• 24860-53-5 1,1’-(biphenyl-4,4’diyl)bis(2-chloroethanone) 
• 92-91-1 biphenyl-4-acetaldehyde 
• 36099-26-0 (R)-2-[(1,1'-biphenyl)-4-yl]oxirane 
• 3418-30-2 2-Chlormethyl-2--<1.3>dioxolan 
• 95620-53-4 1-(biphenyl-4-yl)-2-(4-phenylpiperazin-1-yl)ethanone 

Relevant articles and documents

Synthesis, characterization, theoretical calculations and biochemical evaluation of a novel oxime ligand with complexes

A novel amine containing ketooxime ligand (HBOX) and its Cu(II) and Mn(II) complexes were synthesized, characterized and tested for some of their biological activities. Structural characterization was carried out by elemental analysis, ICP-OES, 1H and 13C NMR, UV–Vis, FT-IR, XRD, TG-DTG, magnetic susceptibility and molar conductivity measurements. Elemental analyses, stoichiometric and spectroscopic data of the metal complexes indicated that the metal:ligand ratio was found to be 1:2 and the metal ions were coordinated to the oxime oxygen and amine nitrogen atoms. Furthermore, DFT/B3LYP method with 6-311G(d,p) and LANL2DZ basis sets were used for full optimization of molecular geometries of the ligand and complexes, respectively. The vibrational frequencies, isotropic chemical shifts (1H and 13C NMR), electronic transition absorption wavelengths, HOMO and LUMO analyses and molecular electrostatic potential (MEP) properties of the synthesized molecules have been calculated. The results obtained experimentally were confirmed by the theoretical data which are in good agreement. Inhibitory capacity of the HBOX was investigated against neoangiogenic factors, vascular endothelial growth factor receptor-2 (VEGFR-2) and cyclooxygenase-2 (COX-2) by molecular docking studies. HBOX bound to COX-2 protein with 2 hydrogen bonds at the lowest energy level which indicates the most stabilized form of the protein ligand complex. Complexes were also tested for their catecholase and phenoxazinone synthase-like activities using spectrophotometric procedures. Catecholase and phenoxazinone synthase-like enzyme activities were spectrophotometrically followed by the increase in absorbance at 400 and 433 nm resulted from the oxidation reaction of 3,5-di-tert-butylcatechol and 2-aminophenol to 3,5-di-tert-butylquinone and 2-aminophenoxazine-3-one, respectively. According to the calculated kobs values, the Mn(II) complex was found to be more active for both enzymes compared to Cu(II).

Poloxamer P85 increases anticancer activity of Schiff base against prostate cancer in vitro and in vivo

Prostate cancer is the second most common cancer among men and the leading cause of death after lung cancer. Development of hormone-refractory disease is a crucial step for prostate cancer progression for which an effective treatment option is currently unavailable. Therefore, there is a need for new agents that can efficiently target cancer cells, decrease tumor growth, and thereby extend the survival of patients in late-stage castration-resistant prostate cancer. In the current study, a novel heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used to evaluate anticancer activity against prostate cancer in vitro and in vivo. Cell proliferation and cytotoxicity were evaluated by cell viability, gene, and protein expression assays in vitro. Results showed that the heterodinuclear copper(II)Mn(II) complex-P85 combination decreased cell proliferation by upregulating the apoptotic gene expressions and blocking the cell proliferation-related pathways. Tramp-C1-injected C57/B16 mice were used to mimic a prostate cancer model. Treatment combination of Schiff base complex and P85 significantly enhanced the cellular uptake of chemicals (by blocking the drug transporters and increased life time), suppressed tumor growth, and decreased tumor volume steadily over the course of the experiments. Overall, heterodinuclear copper(II)Mn(II) complex-P85 showed remarkable anticancer activity against prostate cancer in in vitro and in vivo.

NOVEL 5-[4-(2-BIPHENYL-4-YL-2-OXO-ETHOXY)-BENZYLIDENE]-THIAZOLIDINE-2,4-DIONES, THEIR SYNTHESIS AND USES THEREOF

Disclosed are novel 5-[4-(2-biphenyl-4-yl-2-oxo-ethoxy)-benzylidene]-thiazolidine-2,4-dione compounds of general formula (I), their pharmaceutically acceptable salts, solvates their synthesis and uses thereof, to pharmaceutical compositions containing compounds and to the use of such compounds and composition in medicines either alone or in combination with other compounds.